
Overview
Clebre provides personalized treatment for sleep and breathing disorders. The company offers diagnosis, therapy, and monitoring where the patient sleeps at home, and also supports people who have not adapted to CPAP.
Financials
Revenue history (in k)
From the notes
| Loans and borrowings | $17,039 |
Filing timeliness
2 of 5 financial statements were filed late (the longest delay 179 days for 2023). All were audited by a statutory auditor.
- 202526/06/2026
- 202411/07/2025
- 202310/01/2025
- 202230/06/2023
- 202127/09/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Sleep disorder treatment
- Breathing disorder diagnostics
- Sleep monitoring
- Pulse oximetry testing
Websites
The site is available in: Polish and English.
- clebre.comStrona główna – Clebre – spersonalizowane leczenie zaburzeń snu i oddychaniaWooCommerceWordPress 3.7ElementorStripeLinkedIn AdsGoogle AnalyticsGoogle Tag ManagerRRank MathApache
Authorized Representatives
Manner of representation
Each member of the management board acting independently is authorised to represent the company and to submit all declarations on its behalf.
Supervisory board
Bank accounts
Registered as a VAT taxpayer on 2016-02-15.
36 2490 0005 0000 4600 9150 4049
91 2490 0005 0000 4600 7953 0737
37 2490 0005 0000 4520 5089 7678
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 9, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Olsztyn | |
| Nov 13, 2019 | Aid for research and development projects: industrial research | $663.4K$663,365 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 13, 2019 | Aid for research and development projects: experimental development | $185.4K$185,448 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Spiroclinic sp. z o.o. | $86,493.02 | spiroclinic.pl | ||
| G3 Medical Holding S.A. | $79,789.06 | g3medical.pl | ||
| Neurodiagnostyka sp. z o.o. | $75,311.98 | neurodiagnostyka.com | ||
| Magna Superstes sp. z o.o. | $71,214.32 | totalmedic.pl | ||
| CM7 sp. z o.o. | $50,786.04 | pracowniaeeg.pl | ||
| Sentre sp. z o.o. | $40,450.37 | sentre.com.pl | ||
| Biomed Neurotechnologie sp. z o.o. | $37,598.68 | metodawarnkego.pl | ||
| Health & Security sp. z o.o. | $34,027.71 | psychoterapia-zlapoddech.pl | ||
| Medapp Clinics sp. z o.o. | $26,368.66 | medappclinics.pl | ||
| Centrum Terapii Alma Bełchatów sp. z o.o. | $25,579.97 | centrumalma.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-06-26 | Share capital increase (161,800.00 PLN → 313,376.00 PLN) | |
| 2021-11-19 | Entered in the register |
FAQ
Last updated: 2026-07-10